European Commission Approves Krazati as Targeted Therapy for Advanced NSCLC with KRASG12C Mutation
On January 10, 2024, the European Commission granted its approval to Krazati (adagrasib) as a targeted therapy for individuals suffering ...
Tag: MRTX
SG Americas Securities LLC Invests in Mirati Therapeutics, Inc.: Embracing Innovation in Cancer Treatment
August 14, 2023 - SG Americas Securities LLC Makes a Bold Move by Acquiring New Stake in Mirati Therapeutics, Inc. ...
Popular News
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Trade Desk Shares Face Mounting Pressure as Tariff Warnings Materialize
-
Kraft Heinz Stock: A Contradiction in Market Sentiment
-
NextGen Healthcare Charts Course for Behavioral Health Transformation
-
Regulatory Shift Sparks Potential Breakthrough for DeFi Technologies
